Biotech Values

[DewDiligence]

FDA approves ABBV/ENTA’s Mavyret (G/P)—8-week treatment for all HCV genotypes:

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm570038.htm

ENTA will receive a milestone payment from ABBV that I estimate to be $45-50M. (The exact amount will be known when ENTA issues its own PR.)

Note: The US brand name has a "y" where the EU brand name (Maviret) has an "i".